VAXXINITY INC-A (VAXX) Fundamental Analysis & Valuation

NASDAQ:VAXX • US92244V1044

Current stock price

0.1111 USD
-0.02 (-15.26%)
At close:
0.1107 USD
0 (-0.36%)
After Hours:

This VAXX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. VAXX Profitability Analysis

1.1 Basic Checks

  • In the past year VAXX has reported negative net income.
  • VAXX had a negative operating cash flow in the past year.
  • VAXX had negative earnings in each of the past 5 years.
  • VAXX had a negative operating cash flow in each of the past 5 years.
VAXX Yearly Net Income VS EBIT VS OCF VS FCFVAXX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -20M -40M -60M -80M -100M

1.2 Ratios

  • VAXX's Return On Assets of -128.51% is on the low side compared to the rest of the industry. VAXX is outperformed by 84.27% of its industry peers.
  • VAXX has a Return On Equity of -424.66%. This is in the lower half of the industry: VAXX underperforms 76.92% of its industry peers.
Industry RankSector Rank
ROA -128.51%
ROE -424.66%
ROIC N/A
ROA(3y)-93.82%
ROA(5y)-250%
ROE(3y)-217.4%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
VAXX Yearly ROA, ROE, ROICVAXX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 0 -200 -400 -600 -800

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for VAXX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VAXX Yearly Profit, Operating, Gross MarginsVAXX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 0 -50K -100K -150K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. VAXX Health Analysis

2.1 Basic Checks

  • VAXX has more shares outstanding than it did 1 year ago.
  • Compared to 1 year ago, VAXX has a worse debt to assets ratio.
VAXX Yearly Shares OutstandingVAXX Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M
VAXX Yearly Total Debt VS Total AssetsVAXX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 50M 100M 150M

2.2 Solvency

  • VAXX has an Altman-Z score of -15.07. This is a bad value and indicates that VAXX is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of VAXX (-15.07) is worse than 84.10% of its industry peers.
  • A Debt/Equity ratio of 0.99 indicates that VAXX is somewhat dependend on debt financing.
  • VAXX has a Debt to Equity ratio of 0.99. This is in the lower half of the industry: VAXX underperforms 78.29% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.99
Debt/FCF N/A
Altman-Z -15.07
ROIC/WACCN/A
WACCN/A
VAXX Yearly LT Debt VS Equity VS FCFVAXX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 50M -50M 100M

2.3 Liquidity

  • A Current Ratio of 1.89 indicates that VAXX should not have too much problems paying its short term obligations.
  • VAXX has a Current ratio of 1.89. This is in the lower half of the industry: VAXX underperforms 76.58% of its industry peers.
  • VAXX has a Quick Ratio of 1.89. This is a normal value and indicates that VAXX is financially healthy and should not expect problems in meeting its short term obligations.
  • VAXX has a worse Quick ratio (1.89) than 74.87% of its industry peers.
Industry RankSector Rank
Current Ratio 1.89
Quick Ratio 1.89
VAXX Yearly Current Assets VS Current LiabilitesVAXX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. VAXX Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 25.07% over the past year.
EPS 1Y (TTM)25.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%44.03%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 3.26% on average over the next years.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y17.39%
EPS Next 2Y7.34%
EPS Next 3Y3.5%
EPS Next 5Y3.26%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
VAXX Yearly Revenue VS EstimatesVAXX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2026 2027 2028 2029 2030 50M 100M 150M 200M
VAXX Yearly EPS VS EstimatesVAXX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -0.5 -1 -1.5

More info and screens

Find the best growth stocksShow best growing peers

0

4. VAXX Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for VAXX. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VAXX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VAXX Price Earnings VS Forward Price EarningsVAXX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VAXX Per share dataVAXX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 -0.1 -0.2 -0.3 -0.4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y7.34%
EPS Next 3Y3.5%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. VAXX Dividend Analysis

5.1 Amount

  • No dividends for VAXX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

VAXX Fundamentals: All Metrics, Ratios and Statistics

VAXXINITY INC-A

NASDAQ:VAXX (5/8/2024, 8:24:57 PM)

After market: 0.1107 0 (-0.36%)

0.1111

-0.02 (-15.26%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13
Earnings (Next)08-07
Inst Owners2.07%
Inst Owner Change0%
Ins Owners56.51%
Ins Owner Change0%
Market Cap14.08M
Revenue(TTM)N/A
Net Income(TTM)-56.94M
Analysts87.5
Price Target15.3 (13671.38%)
Short Float %0.31%
Short Ratio0.07
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)36.36%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.05
P/tB 1.05
EV/EBITDA N/A
EPS(TTM)-0.45
EYN/A
EPS(NY)-0.39
Fwd EYN/A
FCF(TTM)-0.46
FCFYN/A
OCF(TTM)-0.45
OCFYN/A
SpS0
BVpS0.11
TBVpS0.11
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -128.51%
ROE -424.66%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-93.82%
ROA(5y)-250%
ROE(3y)-217.4%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.99
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 35.94%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.89
Quick Ratio 1.89
Altman-Z -15.07
F-Score2
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)89.08%
Cap/Depr(5y)94.56%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)25.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%44.03%
EPS Next Y17.39%
EPS Next 2Y7.34%
EPS Next 3Y3.5%
EPS Next 5Y3.26%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y23.21%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-78.04%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-0.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-2.34%
OCF growth 3YN/A
OCF growth 5YN/A

VAXXINITY INC-A / VAXX Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for VAXXINITY INC-A?

ChartMill assigns a fundamental rating of 1 / 10 to VAXX.


What is the valuation status of VAXXINITY INC-A (VAXX) stock?

ChartMill assigns a valuation rating of 0 / 10 to VAXXINITY INC-A (VAXX). This can be considered as Overvalued.


How profitable is VAXXINITY INC-A (VAXX) stock?

VAXXINITY INC-A (VAXX) has a profitability rating of 0 / 10.


How financially healthy is VAXXINITY INC-A?

The financial health rating of VAXXINITY INC-A (VAXX) is 1 / 10.